SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of ...
SAN DIEGO, Feb. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that it has entered into a licensing agreement granting Neopharm Group ("Neopharm" ...
NEW YORK (AP) -- Apricus Biosciences Inc. said Monday that its impotence drug Vitaros has been approved in 10 European countries. The company said Vitaros is now approved in the Netherlands, Germany, ...
SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...
Alprostadil is a widely accepted alternative to the PDE-5 inhibitors for difficult to treat patients, and Vitaros (R), which was determined to be safe and effective by the European Health Authorities ...
SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences, Inc. (“Apricus Bio”) (NASDAQ: APRI), announced today that it has appointed a manufacturer for Vitaros ®, its new treatment for erectile dysfunction ...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about APRI -- Potential Market Size for Vitaros® for Erectile Dysfunction in ...
In 2 randomised controlled trials (RCTs) alprostadil 300 microgram cream statistically significantly improved erectile function and intercourse ability compared with placebo but the average absolute ...
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results